Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension;Modelo teórico de análisis coste-efectividad de la terapia combinada de enalapril-nitrendipino en el tratamiento de la hipertensión arterial

Atencion Primaria

Volumn 31, Issue 6, 2003, Pages 366-371

  Antoñanzas, Fernando ^a,b   Velasco, M ^a   Abbas, I ^a   Pontes, C ^c   Delgadillo, J ^c   Teran M ^c  

^a SOIKOS   (Spain)

^b UNIVERSITY OF LA RIOJA   (Spain)

^c Vita Invest SA   (Spain)

Author keywords

Combined therapy; Cost effectiveness analysis; Enalapril; Hypertension; Nitrendipine

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NITRENDIPINE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MODEL; NATIONAL HEALTH SERVICE; SPAIN; COST BENEFIT ANALYSIS; THEORETICAL MODEL;

COST-BENEFIT ANALYSIS; ENALAPRIL; HUMANS; HYPERTENSION; MODELS, THEORETICAL; NITRENDIPINE;

EID: 0042066739     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0212-6567(03)70700-8     Document Type: Article

References (24)

1. Banegas JR, Rodríguez-Artalejo F, Graciani A, Villar F, Guailar-Castillon P, De la Cruz J. Epidemiologia de la hipertensión arterial en España. Prevalencia, conocimiento y control. Hipertensión 1999;16:315-22.
2. Plans-Rubio P. Cost-effectiveness of cardiovascular prevention program in Spain. Int J Technol Assess Health Care 1998;14:320-30.
3. González J, Llinás M, Rodríguez F, Salazar F. Efectos de la administración de un IECA y un antagonista del calcio en hipertensión. Hipertensión 1997;14:137-40.
4. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
5. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendation for use. Am Fam Phys 2000;61:3049-56.
6. Latts L. Impact of combination therapy on managed care. Am J Manag Care 1999;5(Suppl 7):456-62.
7. Hillerman D. Cost effectiveness of combination therapy. Am J Manag Care 1999;5(Suppl 7):449-55.
8. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
9. Reverte-Cejudo D, Moreno Palomares JJ, Ferreira Pasos EM. Hipertensión arterial: actualización de su tratamiento. Inf Ter Sist Nac Salud 1998;22:81-94.
10. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised doubled-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
11. Staessen J, Thisj L, Fagard RH, Birkenhager WH, Arabidze G, Babeanu S, et al. Calcium channel blockade and cardiovascular prognosis in the european trial on isolated systolic hypertension. Hypertension 1998;32:410-6.
12. Wenzel UO, Helmchen U, Schoeppe W, Schwietzer G. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 1994;1:114-22.
13. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001;14:963-8.
14. Pool J, Kaihlanen P, Lewis G, Ginsberg D, Oparil S, Glazer R, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001;15:495-8.
15. González C, Sanz P, Álvarez S, Bermejo F, Gallego P, La Torre del Carmen L. Does the system of prescription insurance the therapy compliance of hypertensive patients? Aten Prim 1999;24:281-4.
16. Mar J, Rodríguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001;19:149-55.
17. Márquez-Contreras E, Casado J, Ramos J, Sáenz S, Moreno JP, Celotti B, et al. Influencia del cumplimiento terapéutico en los niveles de presión arterial en el tratamiento de la hipertensión arterial. Hipertensión 1998;15:133-9.
18. Puigventos F, Llodra V, Vilanova M, Delgado O, Ferreruela M, Forteza-Rey J, et al. Compliance with hypertension treatment: 10 years of publications in Spain. Med Clin (Barc) 1997;109:702-6.
19. Roca-Cusachs A, Torres F, Horas M, Ríos J, Calvo G, Delgadillo J, et al. Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design. J Cardiovasc Pharmacol 2001;38:840-9.
20. Kroning B, Pittrow DB, Kirch W, Wezel D, Weidinger G. Different concepts in first-line treatment of essential hypertension. Comparison of low-dose reserpine-thiazide combination with Nitrendipine monotherapy. German Reserpine in Hypertension study Group. Hypertension 1997;29:651-8.
21. Prisant LM, Weir MR, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-66.
22. Rovira J, Segú JL, Figueras M, Brosa M, Artés M, Ollé A, et al. Estudio coste-efectividad del tratamiento de la hipertensión ligera-moderada con inhibidores de la enzima convertidora de la angiotensina. Hipertensión 1996;13:322-30.
23. McMurray J. The health economics of the treatment of hyperlipidemia and hypertension. Am J Hypertens 1999;12(10 Pt 2):99-104.
24. Lindholm L, Hallgren CG, Boman K, Margren K, Weinehall L, Ogren JE. Cost-effectiveness analysis with defined budget: how to distribute resources for prevention of cardiovascular disease? Health Policy 1999;48:155-70.